Table 1. Baseline characteristics of the study population (n = 129): clinical parameters, medication and laboratory measurements.
| Characteristics | Value |
|---|---|
| Clinical parameters | |
| Age, years | 57.0 (46.0–69.1) |
| Male, n (%) | 78 (60) |
| Body mass index, kg/m2 | 25.3 ± 4.6 |
| Caucasian, n (%) | 123 (95) |
| Deceased donor transplant, n (%) | 80 (62) |
| History of acute rejection, n (%) | 49 (38) |
| Graft vintage, years | 5.0 (2.0–12.0) |
| Systolic BP, mmHg | 132 ± 17 |
| Diastolic BP, mmHg | 79 ± 12 |
| Current smoker, n (%) | 12 (9.3) |
| Etiology of kidney disease, n (%)* | |
| Diabetes | 8 (6.2) |
| Hypertension | 27 (20.9) |
| Glomerulonephritis | 29 (22.5) |
| Polycystic kidney disease | 24 (18.6) |
| Others (tubulointerstitial nephritis, reflux, …) | 68 (52.7) |
| Medication, n (%) | |
| ACEi/ARB | 66 (51.2) |
| Calcium channel blockers | 57 (44.2) |
| Diuretics | 14 (10.9) |
| Beta-blockers | 72 (55.8) |
| Statins | 85 (66.9) |
| Calcium supplementation | 91 (70.5) |
| 1.25OH-vitamin D supplementation | 15 (11.6) |
| 25OH-vitamin D supplementation | 113 (87.6) |
| Laboratory measurements | |
| Creatinine, micromol/l | 128 ± 47 |
| eGFR ml/min per 1.73m2 ** | 55 ± 20 |
| Albumin, g/l | 37.2 ± 3.5 |
| Corrected calcium, mmol/l | 2.4 ± 0.14 |
| Phosphate, mmol/l | 1.1 ± 0.2 |
| Magnesium, mmol/l | 0.72 ± 0.1 |
| 25-hydroxyvitamin D, nmol/l (n = 125) | 68 ± 22 |
| Parathyroid hormone, pmol/l(n = 126) | 8.5 (6.0–10.8) |
| Hemoglobin, g/l | 129 ± 15 |
| FGF23, RU/ml | 39.3 (27.7–54.6) |
| Klotho, pg/ml | 744 ± 246 |
| T50, min | 285 ± 61 |
| Spot urine protein/creatinine ratios, g/24h (n = 119) | 0.12 (0.07–0.25) |
| Albuminuria, n (%) | |
| • <30 mg/g | 55 (42.6) |
| • 30-300mg/g | 51 (39.5) |
| • >300mg/g | 23 (17.8) |
Values reported as numbers and %, mean±SD, or median (interquartile ranges) as appropriate.
*One patient may have more than one etiology to their kidney disease.
**eGFR (estimated Glomerular Filtration Rate) was calculated according to the Chronic Kidney Disease Epidemiology Collaboration equation.
ACEi/ARB, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker.BP: Blood Pressure; FGF23: Fibroblast growth factor 23; T50: Calcification propensity.